ClinicalTrials.gg
RecruitingNCT06832644CVRISK-ITUpdated Nov 6, 2026

Novel Risk Prediction Approaches for the Primary Prevention of Cardiovascular Diseases in Italy: the CVRISK-IT Trial (CVRISK-IT)

An interventional study of Lifestyle Management in Cardiovascular Risk and Genetic Cardiovascular Risk, sponsored by IRCCS Policlinico S. Donato. Recruiting at 17 sites in Italy. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by IRCCS Policlinico S. Donato · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Nov 6, 2026Site recruiting status changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30,000
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

The CVRISK-IT study aims to evaluate the health benefit of measuring genetic and imaging risk information in men and women considered at 'low-to-moderate' or 'high' risk of developing cardiovascular diseases (CVD) in a randomized controlled trial in Italian primary care settings. Our primary objective is to answer a fundamental question in the prevention and prediction of CVD in Italy and globally: is there any benefit in including additional information (such as genetic and/or imaging data) in estimating risk, in conjunction with lifestyle advice and medical treatment for primary prevention of CVD?

As a key secondary objective of the CVRISK-IT study, the goal is to build a large bioresource with clinical information and biological samples to facilitate a new generation of discovery and translational research that will advance understanding of the genetic, molecular and behavioural determinants as well as mechanisms of multiple chronic diseases in the Italian population. By contributing to the Rete Cardiologica database and the BBDCARDIO biobank, the CVRISK-IT study will also serve as a cornerstone for future investigations into the development and testing of early diagnostic technologies and preventive (or 'personalised precision health') interventions for chronic diseases.

Read the detailed description

This multicenter, open randomized trial will investigate the effects of providing additional CVD risk information alongside personalised lifestyle advice and medical treatment in a primary prevention context across Italy. Healthy individuals aged 40 to 80 years, with no prior history of CVD or diabetes, will be recruited in two phases from the cohort of 17 participating IRCCS across Italy and affiliated enrolling centers. The population enrolled in this study consists of subjects who have never participated in other cardiovascular prevention studies of the Rete Cardiologica.

Phase 1 - Identification of the study population and development of the bioresource: various recruitment sources will be used, including institutions, primary care centres/services, government agencies, occupational health services, and volunteer organizations (e.g., blood donors). Participants will provide informed consent, a blood sample, and complete an electronic questionnaire. Approximately 30,000 individuals will be recruited and assessed using SCORE2/SCORE2-OP risk prediction models. Those identified as 'very high' risk will receive immediate medical treatment and will not proceed to phase 2.

Phase 2 - Randomization and novel risk prediction interventions: Participants identified as 'low-to-moderate' or 'high' CVD risk during phase 1 will be randomized, following a 2x2 factorial design into four groups within 1 week upon enrolment: a control group (no additional risk information), and three intervention groups (genetic, imaging-based and genetic + imaging-based risk information). The goal is to randomize around 12,000 participants in phase 2 (\~3,000 per trial arm). All individuals will receive tailored lifestyle advice along with medical treatment based on their newly estimated CVD risk. The remaining 18,000 participants who won't proceed to phase 2 will still be involved in the study and contacted through a phone call follow-up with specialist at the 5◦ and 10◦ year.

02

Conditions studied

  • Cardiovascular Risk
  • Genetic Cardiovascular Risk

Keywords

  • Primary Prevention
  • Cardiovascular Risk
  • SCORE2/2-OP
03

In context

Lead sponsor

IRCCS Policlinico S. Donato is the lead sponsor of 105 studies on the registry; 53 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 40-80 years
  • Apparently healthy individuals without previous medical history of CVD or diabetes (based on medical diagnosis)
  • Participant recruitment arranged only at selected IRCCS (and associated Spokes) as part of the 'Rete Cardiologica'
  • Participants must have signed the and Data Privacy Treatment forms
  • Participants must have a personal e-mail address and internet connection

Exclusion criteria

Exclusion Criteria:

  • Age ≤40 or ≥80 years
  • Individuals have previous medical history related to CVD (e.g., heart failure, congenital heart disorder, coronary heart disease) based on medical diagnosis
  • Candidates have previously participated in clinical studies of 'Rete Cardiologica' (e.g., PREVITAL)
  • Medical diagnosis of mental disorders
  • Pregnancy based on self-reported information
  • Previous history of type 1 or type 2 diabetes (based on medical diagnosis)
  • Oncology patients (based on physician indication)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
30,000 participants (estimated)

Study arms

  • No intervention
    Control

    No additional cardiovascular risk information/recommendation is provided to the subject other than SCORE2/SCORE2-OP results of phase I. Thereby, the control group does not undergo neither imaging nor genetic analysis.

  • Experimental
    Imaging

    Subjects randomized in the imaging arm receive personalized recommendations on lifestyle and, if necessary, therapeutic intervention based on imaging data analysis (i.e., carotid ultrasound or calcium score)

    Behavioral: Lifestyle Management

  • Experimental
    Polygenic Risk Score (PRS)

    Subjects randomized in this arm receive personalized recommendations on lifestyle and, if necessary, therapeutic intervention based on polygenic risk score (PRS) analysis obtained from blood samples collected at the baseline visit

    Behavioral: Lifestyle Management

  • Experimental
    Imaging and Polygenic Risk Score (PRS)

    Subjects randomized in this arm receive personalized recommendations on lifestyle and, if necessary, therapeutic intervention based on both imaging data (e.g., carotid ultrasound and/or calcium score) and genetic analysis (e.g., PRS).

    Behavioral: Lifestyle Management

Interventions

  • BehavioralLifestyle Management

    All individuals will receive tailored lifestyle advice along with medical treatment based on their newly estimated CVD risk. The control group will also receive lifestyle advice along with medical treatment based only on their CVD risk provided at the baseline visit during phase I.

06

What researchers measure

Primary outcomes

  1. Change in CVD risk using SCORE2/SCORE2-OP

    The primary short-term outcome (i.e., 12 months after communication of the newly estimated CVD risk, following the randomisation step) is the change in CVD risk measured using SCORE2/SCORE2-OP risk prediction models. The CVD risk categories used to classify healthy people according to these scores are: 1) Low-to-moderate CVD risk: \<50 years = \<2.5 %; 50-69 years = \<5%; ≥ 70 years = \<7.5%. High CVD risk: \<50 years = 2.5 to \<7.5%; 50-69 years = 5 to \<10%; ≥ 70 years 7.5 to \<15%; Very high CVD risk: \<50 years = ≥7.5%; 50-69 years = ≥10%; ≥ 70 years = ≥ 15%.

    Time frame: 12 months

Secondary outcomes

  1. Change in cardiovascular modifiable risk factors

    Secondary short-term outcomes will include changes in objectively measured risk factors, such as cholesterol levels (i.e., total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides) (mg/dl)

    Time frame: 12 months

  2. Change in cardiovascular modifiable risk factors

    Secondary short-term outcomes will include changes in objectively measured risk factors, such as blood pressure which will be measured 3 times in a row, and its average calculated (mmHg)

    Time frame: 12 months

  3. Change in cardiovascular modifiable risk factors

    Secondary short-term outcomes will include changes in objectively measured risk factors, such as smoking habits (e.g., switch from "usual smoker" to "not smoking anymore" categories)

    Time frame: 12 months

  4. Change in CVD prevention-drugs prescription

    Secondary short-term outcomes will include changes in CVD prevention-drugs prescription with respect to the baseline visit

    Time frame: 12 months

  5. Evaluation of participant's adherence to ESC recommendations

    By means of validated questionnaires, the assessment of participants' adherence to the lifestyle and dietary guidelines of the European Society of Cardiology (ESC) will be performed. If and where applicable, drugs prescription adherence will be evaluated as well as psychological outcomes

    Time frame: 12 months

Other outcomes

  1. CVD events recording in long-term period

    The long-term outcomes will include the registration of CVD events in all enrolled participants in the long-term period (e.g., non-fatal myocardial infarction, acute coronary syndrome, percutaneous transluminal coronary angioplasty (PTCA), Coronary artery bypass grafting (CABG), non-fatal stroke), CVD mortality, and total mortality

    Time frame: 5-10 years

07

Study locations

7 of 17 sites recruiting
08

References and documents

Publications

  • Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, Gale CP, Maggioni AP, Petersen SE, Huculeci R, Kazakiewicz D, de Benito Rubio V, Ignatiuk B, Raisi-Estabragh Z, Pawlak A, Karagiannidis E, Treskes R, Gaita D, Beltrame JF, McConnachie A, Bardinet I, Graham I, Flather M, Elliott P, Mossialos EA, Weidinger F, Achenbach S; Atlas Writing Group, European Society of Cardiology. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022 Feb 22;43(8):716-799. doi: 10.1093/eurheartj/ehab892. PubMed 35016208 ↗
  • Di Angelantonio E, Piepoli M, Castelvecchio S, Barberio C, Chiarello C, Cerri A, Boveri S, Cardani R, Ambrogi F, Guelfi S, Baldassarre D, Colombo G, Amato M, Baetta R, Arbustini E, Liuzzo G, Kaptoge S, Severino A, Ferrante G, La Rovere MT, Parati G, Pengo MF, Latini R, Roncaglioni MC, Rigoni M, De Curtis A, Frati L, Ameri P, Camici PG, Volpe M, Menicanti L. Integrating genetic and imaging information to enhance cardiovascular risk stratification: rationale and design of the CVRISK-IT randomised controlled trial. Eur Heart J Qual Care Clin Outcomes. 2026 Mar 4:qcag032. doi: 10.1093/ehjqcco/qcag032. Online ahead of print. PubMed 41778587 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Jan 2028, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2025
First posted
Feb 18, 2025
StartActual
Jan 22, 2025
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2030
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. Irccs Inrca is now Recruiting
Show site
  • IRCCS Cardiologico Monzino · Milan, Italy
Show 1 removed
  • IRCCS Cardiologico Monzino · Milan, Italy
Nov 6, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Irccs Inrca · Ancona, ItalyContact none listed→•••3450Contact none listed→r•••@inrca.it
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    1 site added, 1 site removed. Irccs Inrca is now Recruiting
    Show site
    • IRCCS Cardiologico Monzino · Milan, Italy
    Show 1 removed
    • IRCCS Cardiologico Monzino · Milan, Italy
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Irccs Inrca · Ancona, ItalyContact none listed→•••3450Contact none listed→r•••@inrca.it
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06832644
Collaborators
Centro Cardiologico Monzino, Fondazione IRCCS Policlinico San Matteo di Pavia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Istituti Clinici Scientifici Maugeri SpA, Istituto Di Ricerche Farmacologiche Mario Negri, IRCCS Multimedica, Istituto Neurologico Mediterraneo Neuromed S. R. L, IRCCS San Raffaele, IRCCS San Raffaele Roma, IRCCS SYNLAB SDN, Istituto Clinico Humanitas, Istituto Nazionale di Ricovero e Cura per Anziani, The Mediterranean Institute for Transplantation and Advanced Specialized Therapies, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Ospedale Policlinico San Martino, Istituto Auxologico Italiano
Responsible party
Lorenzo Menicanti (MD, IRCCS Policlinico S. Donato) — Principal investigator
First posted
Feb 18, 2025
Start date
Jan 22, 2025
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Nov 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion